To be effective in symptomatic AD, such a therapy has first to bring down the levels of iAβ sufficiently (i.e., below the T1 threshold) to de-activate its production in the AβPP-independent pathway; it is apparently incapable of this. Here, APP is linked to Alzheimer disease.